This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
vaccines: Archive
Should You Buy Churchill Downs (CHDN) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CHDNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Market Bears Take The Bulls By The Horns As Q4 Kicks Off
by Daniel Laboe
We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows
REGNPositive Net Change AAPLNegative Net Change MRKPositive Net Change PEPPositive Net Change ILMNPositive Net Change MRNANegative Net Change STZPositive Net Change TSLANegative Net Change FRSHNegative Net Change UBERNegative Net Change BNTXNegative Net Change WRBYNegative Net Change TOSTPositive Net Change
apparel medical oil-energy ride-hailing transportation vaccines
J&J (JNJ) Starts Phase III Study on RSV Vaccine in Older Adults
by Zacks Equity Research
J&J (JNJ) starts the phase III study on its RSV vaccine candidate in adults aged 60 years and above.
GSKPositive Net Change JNJPositive Net Change PFEPositive Net Change NVAXNegative Net Change
medical pharmaceuticals vaccines
Semtech (SMTC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SMTCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data
by Zacks Equity Research
Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.
SNYNegative Net Change GSKPositive Net Change PFEPositive Net Change MRNANegative Net Change
pharmaceuticals vaccines
Pfizer (PFE) Begins COVID Prevention, mRNA Flu Vaccine Studies
by Zacks Equity Research
Pfizer (PFE) begins new studies on its oral antiviral pill for the prevention of COVID-19 infection and a potential mRNA influenza vaccine.
JNJPositive Net Change PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change
pharmaceuticals vaccines
SQM (SQM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SQMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing
by Zacks Equity Research
On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility
AZNNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical vaccines
Should You Buy Brooks Automation (BRKS) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BRKSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot
by Kinjel Shah
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.
AZNNegative Net Change NVSPositive Net Change JNJPositive Net Change PFEPositive Net Change LLYPositive Net Change ABBVPositive Net Change BNTXNegative Net Change
pharmaceuticals vaccines
J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data
by Sweta Jaiswal, FRM
The positive data update has put the spotlight on a number of ETFs that could benefit from their high exposure to Johnson & Johnson.
JNJPositive Net Change XLVPositive Net Change IYHPositive Net Change IHEPositive Net Change FTXHPositive Net Change IEIHPositive Net Change
etfs medical vaccines
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.
PFEPositive Net Change MRNANegative Net Change PJPPositive Net Change IHEPositive Net Change FDLPositive Net Change IEIHPositive Net Change BNTXNegative Net Change
etfs medical vaccines
Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People
by Zacks Equity Research
FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.
JNJPositive Net Change PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change
pharmaceuticals vaccines
J&J's (JNJ) New Data Shows COVID-19 Booster Ups Protection
by Zacks Equity Research
J&J's (JNJ) data showed that a booster dose of its vaccine generated 94% efficacy against mild-to-severe COVID-19 in the United States. The data also confirmed that even one dose offers strong and long-lasting protection.
JNJPositive Net Change PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change
vaccines
After Golden Cross, Pure Storage (PSTG)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
PSTGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Contagion Fears Squeeze Pre-Market Futures
by Mark Vickery
It's difficult to know what's going on in the minds of the Chinese market authorities, but for those great American companies less reliant on the Chinese economy, it may be a good time to bring out our wish-list.
GSNegative Net Change CATNegative Net Change PFEPositive Net Change BABAPositive Net Change BNTXNegative Net Change
vaccines
FDA Panel Vetoes PFE/BNTX Third Jab for All, Vaccine Stocks Down
by Kinjel Shah
Pfizer (PFE) and Moderna (MRNA) are the only two companies that have submitted data and are seeking approval for a booster or "third" dose of their COVID-19 vaccines.
JNJPositive Net Change PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change
vaccines
Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well
by Zacks Equity Research
Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.
AZNNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical vaccines
Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News
by Sweta Jaiswal, FRM
Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.
MRNANegative Net Change IBBNegative Net Change BBHPositive Net Change IDNANegative Net Change
biotechnology biotechs etfs vaccines
Delta and the Q3 Earnings Season
by Sheraz Mian
The ongoing resurge in Covid infections has started weighing on near-term economic outlook, with estimates of Q3 GDP growth sharply coming down in recent days.
JPMPositive Net Change NKENegative Net Change ORCLNegative Net Change COSTNegative Net Change FDXNegative Net Change
earnings messenger-rna vaccines
Workday (WDAY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
WDAYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab
by Zacks Equity Research
Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.
AZNNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical vaccines
After Golden Cross, Qualys (QLYS)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
QLYSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
AstraZeneca's (AZN) Ultomiris Gets EU Nod for Rare Disease in Kids
by Zacks Equity Research
AstraZeneca's (AZN) Ultomiris receives expanded approval in the EU to treat children and adolescents with PNH, a rare disease.
REGNPositive Net Change AZNNegative Net Change VRTXNegative Net Change MRNANegative Net Change
medical pharmaceuticals vaccines
After Golden Cross, Whitestone (WSR)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
WSRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines